Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers

NCT02393690 is registered in ClinicalTrials.gov with Academic and Community Cancer Research United as lead sponsor.

NCT NCT02393690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02393690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers
Lead sponsor
Academic and Community Cancer Research United
Phase
Phase 2
Overall status
Completed
Start date
May 4, 2015
Completion date
December 31, 2023
Enrollment
60 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic thyroid gland carcinoma, poorly differentiated thyroid gland carcinoma, recurrent thyroid gland carcinoma, stage iv thyroid gland follicular carcinoma ajcc v7, stage iv thyroid gland papillary carcinoma ajcc v7, stage iva thyroid gland follicular carcinoma ajcc v7, stage iva thyroid gland papillary carcinoma ajcc v7, stage ivb thyroid gland follicular carcinoma ajcc v7, stage ivb thyroid gland papillary carcinoma ajcc v7, stage ivc thyroid gland follicular carcinoma ajcc v7, stage ivc thyroid gland papillary carcinoma ajcc v7